Physician profile
Kent Doherty
NPI 1477689909
$965.10
in general payments reported to CMS, 2019-2025
20 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.28 · 2020: $47.04 · 2021: $99.85 · 2022: $259 · 2023: $175 · 2024: $171 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $136.52 | 2021-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $102.53 | 2020-2024 | |
| Cranial Technologies, INC | $94.59 | 2020-2025 | Doc Band |
| Sanofi Pasteur INC. | $67.27 | 2022-2023 | |
| Glaxosmithkline, LLC. | $63.96 | 2022-2025 | Bexsero |
| Takeda Pharmaceuticals U.S.A., INC. | $63.85 | 2019-2022 | |
| Neos Therapeutics, Lp | $50.45 | 2024-2025 | Cotempla Xr-Odt, Adzenys Xr-Odt |
| Kaleo, INC. | $43.19 | 2019-2023 | Auvi-Q |
| Merck Sharp & Dohme LLC | $41.24 | 2022-2023 | Gardasil 9, Vaxelis, M-M-R II |
| Supernus Pharmaceuticals, INC. | $39.78 | 2022-2025 | Qelbree |
| Pfizer INC. | $37.14 | 2023-2024 | |
| Adlon Therapeutics L.P. | $36.28 | 2021 | |
| Seqirus USA INC | $36.06 | 2022-2025 | Flucelvax |
| Sanofi-Aventis U.S. LLC | $30.61 | 2024 | |
| Tris Pharma INC | $28.40 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $24.71 | 2025 | Neffy |
| Boston Scientific Corporation | $22.94 | 2019 | |
| Alk-Abello, INC | $16.15 | 2021 | |
| Sobi, INC | $16.11 | 2022 | |
| Noven Therapeutics, LLC | $13.32 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Doherty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.